Migraine Prophylaxis Treatment Options
First-Line Pharmacologic Agents
For adults with episodic migraine requiring prophylaxis, initiate treatment with propranolol (80-240 mg/day), metoprolol (50-100 mg twice daily or 200 mg modified-release once daily), topiramate (50-100 mg/day), or divalproex sodium/valproate (500-1500 mg/day or 800-1500 mg/day). These agents have the strongest evidence base and are recommended as first-line options by multiple high-quality guidelines 1, 2, 3.
Beta-Blockers
- Propranolol (long-acting) 80-160 mg/day represents the most established first-line preventive agent with the strongest evidence base 2, 1.
- Metoprolol 50-100 mg twice daily (or 200 mg modified-release 200 mg once daily) provides comparable efficacy to propranolol 2, 1.
- Timolol 20-30 mg/day has demonstrated preventive efficacy in clinical trials 1, 2.
- Screen for contraindications before prescribing: asthma, cardiac failure, Raynaud phenomenon, atrioventricular block, and depression 2.
Anticonvulsants
- Topiramate 50-100 mg/day is particularly advantageous in patients with obesity due to weight loss effects 2, 1.
- Start at low doses and titrate slowly to minimize adverse effects including cognitive slowing, paresthesias, and kidney stones 2.
- Contraindications include: history of kidney stones, pregnancy, lactation, and glaucoma 2.
- Divalproex sodium (500-1500 mg/day) or valproate (800-1500 mg/day) have proven efficacy but carry significant restrictions 1.
- Valproate is absolutely contraindicated in individuals of childbearing potential due to teratogenic effects 2, 1.
Angiotensin Receptor Blockers
- Candesartan 16-32 mg/day is a reasonable alternative when beta-blockers and topiramate cannot be used 2, 1.
- Contraindicated with concurrent aliskiren use 2.
Second-Line Options
If first-line agents fail after adequate trial (2-3 months at target dose), consider amitriptyline (30-150 mg/day) or alternative beta-blockers before progressing to newer agents. 1, 2
- Amitriptyline 30-150 mg/day has established efficacy but more adverse events than first-line options 1, 3.
- Atenolol 25-100 mg twice daily and bisoprolol 5-10 mg once daily are probably effective second-line beta-blockers 2.
- Venlafaxine is considered second-line due to less supporting evidence 3.
Third-Line and Specialized Treatments
CGRP-Targeted Therapies
Reserve CGRP monoclonal antibodies for patients who have failed two to three conventional preventive medications due to cost considerations and insurance restrictions 2, 1, 4.
- Erenumab 70-140 mg monthly subcutaneous 2, 4.
- Fremanezumab 225 mg monthly or 675 mg quarterly subcutaneous 2, 4.
- Galcanezumab monthly subcutaneous 2, 4.
- Eptinezumab intravenous is the only IV anti-CGRP ligand monoclonal antibody 4.
- These agents show increased adherence compared to non-specific preventives and benefit patients who failed conventional treatments 5.
OnabotulinumtoxinA
- OnabotulinumtoxinA 155-195 units injected into 31-39 sites every 12 weeks is evidence-based specifically for chronic migraine (≥15 headache days/month) 2, 3.
- As effective as other medications with better tolerability and lower discontinuation rates 3.
- Typically requires specialist referral 2.
Treatment Algorithm and Implementation
Initiation Criteria
Consider prophylaxis when patients experience: 1
- Two or more attacks per month producing disability lasting 3+ days
- Contraindication to or failure of acute treatments
- Acute medication use more than twice weekly (NSAIDs ≥15 days/month, triptans ≥10 days/month)
- Severe debilitating headaches despite adequate acute treatment
Dosing Strategy
- Start at low doses and titrate gradually over 2-3 months to reach target dose before evaluating efficacy 2, 1.
- Allow minimum 2-3 months at target dose before declaring treatment failure 2, 1.
- Treatment success is defined as ≥50% reduction in monthly headache days 2.
Sequential Approach
- First, optimize acute treatment and address modifiable triggers (hydration, sleep, physical activity) 1.
- Initiate first-line agent based on comorbidities: beta-blocker for hypertension/anxiety, topiramate for obesity, avoid valproate in childbearing potential 2, 1.
- If inadequate response after adequate trial, switch to alternative first-line medication rather than immediately escalating 2, 1.
- Progress to second-line options only after failure of multiple first-line agents 2.
- Consider CGRP antibodies after failure of 2-3 conventional preventives 2, 1.
Monitoring and Adjustment
- Use headache diaries to objectively track frequency, severity, and acute medication use 2, 1.
- Re-evaluate after 2-3 months at target dose to determine response and need for adjustment 2, 1.
- Consider tapering after 6-12 months of sustained success to minimize long-term medication exposure 2.
Critical Pitfalls to Avoid
- Do not prescribe valproate to individuals of childbearing potential (absolute contraindication) 2, 1.
- Avoid premature discontinuation due to inadequate dosing or insufficient trial duration (minimum 2-3 months at target dose) 2, 1.
- Prevent medication-overuse headache by limiting simple analgesics to ≤15 days/month and triptans to ≤10 days/month 2, 1.
- Screen for beta-blocker contraindications (especially asthma and cardiac conditions) before prescribing 2.
- Monitor for topiramate adverse effects including cognitive slowing, paresthesias, and kidney stones 2.
- Educate patients about realistic timelines: improvement occurs gradually over weeks to months, not immediately 1, 2.
Special Populations
Children and Adolescents
- Discuss with patients/families whether to use preventive medication, since placebo was as effective as studied medications in many pediatric trials 1.
- Evidence supports amitriptyline combined with cognitive behavioral therapy, topiramate, and propranolol for pediatric migraine prevention 1.
- Counsel about teratogenic effects of topiramate and valproate, advise effective birth control and folate supplementation when relevant 1.